Tests a new small PET scanner for brain amyloid plaques in cognitive impairment
Compares a new PET scanner's brain images with standard scanners in adults with cognitive impairment.
Plain-language title generated from the registry record
Registry title: Radialis PET Imager for the Assessment of Neuritic Amyloid Plaque Burden
Key facts
- Where
- Toronto, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cognitive impairment who are already having a brain amyloid PET scan (18F-Florbetaben) as part of their usual care. They will have one extra scan with a new PET imager.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Cognitive impairment, including Alzheimer's Disease.
- Earlier treatment
- Must be having the standard of care brain 18F-Florbetaben PET scan.
Main reasons for not taking part
- Cannot give informed consent
- Cannot lie still for an extra scan of about 30-45 minutes
- Has a reason not to have a PET scan under the centre's safety rules, such as pregnancy
Read by machine on 9 November 2026.
Where in Canada
- University Health Network, TorontoToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT06757569
- Record updated
- 3 February 2026
- Original description
The standard or usual workup for cognitive impairment, including Alzheimer's Disease, may include brain amyloid PET with PET/CT or PET/MR imaging. Amyloid PET is the standard imaging that was requested for you by your referring physician. This imaging can visualize your brain.Read full original descriptionShow less
Radialis PET Imager for the Assessment of Neuritic Amyloid Plaque Burden
The standard or usual workup for cognitive impairment, including Alzheimer's Disease, may include brain amyloid PET with PET/CT or PET/MR imaging. Amyloid PET is the standard imaging that was requested for you by your referring physician. This imaging can visualize your brain.
With the development of new therapies for Alzheimer's disease which require amyloid PET imaging, there will be a significant increase in the number of PET scans needed to provide care to all patients. There are likely not enough PET scanners in Canada to meet this demand. Therefore, we are searching for comparable alternatives. One of the imaging devices that was introduced in the clinic is the Radialis PET imager (or RPI). Health Canada, the regulatory body that oversees the use of devices in Canada, has not approved the sale or use of the Radialis PET imager. Health Canada has allowed the Radialis PET imager to be used in this study. We would like to see whether the images obtained for the brain are comparable to those obtained from a PET/CT or PET/MRI scanner. It is a new type of PET imaging device for patients undergoing a PET scan and has been used in Canada for research. RPI is experimental, meaning that this PET scan is not used routinely in patients' care.
In comparison to the standard PET devices, RPI is smaller and mobile, meaning it can be moved around easily for use. Also, it can be installed in imaging centers at a lower cost. These advantages make RPI an interesting alternative to the standard PET. However, the performance of this new imaging device has not been tested in Amyloid PET imaging in particular.
As you may know, in a PET scan, we inject a radioactive material (called tracer) which can circulate in your body and visualize specific areas in your body. In amyloid PET we inject an amyloid tracer that goes to the brain and lights up certain regions of the brain.
RPI was previously tested for other PET tracers and was shown to be comparable to standard PET devices. Thus, by changing the PET material (to Amyloid), we are pursuing the same aim: comparison of RPI with standard PET devices and see whether it can provide comparable images of the brain.
Inclusion: Age ≥18 years; Patients with cognitive impairment undergoing the standard of care brain 18F-Florbetaben PET imaging; Patients who can remain still for an additional scan of approximately 30-45 minutes; -.
Exclusion: Inability to provide informed consent. 2. Contraindication for PET examination as per institutional safety guidelines, including but not limited to pregnancy or inability to remain still for PET examination; -.